High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)

Leukemia and Lymphoma

Volumn 48, Issue 7, 2007, Pages 1299-1306

  Weide, Rudolf ^a   Hess, Georg ^b   Köppler, Hubert ^a   Heymanns, Jochen ^a   Thomalla, Jörg ^a   Aldaoud, Ali ^c   Losem, Christoph ^a   Schmitz, Stefan ^d   Haak, Ursula ^e   Huber, Christoph ^b   Unterhalt, Michael ^f   Hiddemann, Wolfgang ^f   Dreyling, Martin ^f  

^a Praxisklinik for Hematology and Oncology   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Gemeinschaftspraxis Hematology/Medical Oncology   (Germany)

^d Scientific Institute for Hematology and Oncology   (Germany)

^e Krankenhaus Martha Maria Halle Dölan   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bendamustine; Immunochemotherapy; Indolent lymphoma; Mitoxantrone; Rituximab

Indexed keywords

BENDAMUSTINE; MITOXANTRONE; RITUXIMAB;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLEEDING; CANCER GRADING; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HEART ARRHYTHMIA; HEART DISEASE; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INFECTION; LEUKOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RETREATMENT; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LOW-GRADE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MITOXANTRONE; NITROGEN MUSTARD COMPOUNDS; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34447549127     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701361828     Document Type: Article

References (19)

1. Hiddemann, W., Kneba, M. and Dreyling, M. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-grade Lymphoma Study Group. Blood, 106, pp. 3725-3732.
2. Marcus, R., Imrie, K. and Belch, A. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, pp. 1417-1423.
3. Herold, M., Pasold, R. and Srock, S. (2004) Results of a prospective randomized open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma (MCL). Blood, 104
4. Forstpointer, R., Dreyling, M. and Repp, R. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group. Blood, 104, pp. 3064-3071.
5. Leoni, L. M., Bailey, B. and Reifert, J. (2003) SDX-105 (Bendamustine), a clinically active antineoplastic agent possesses a unique mechanism of action. Blood, 102
6. Bremer, K. and Roth, W. (1996) Bendamustine, a low toxic nitrogen-mustard derivative with high efficacy in malignant lymphomas. Tumordiagn u Ther, 17, pp. 1-6.
7. Bremer, K. (2002) High rates of long lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low grade non-Hodgkin's lymphomas. J Cancer Res Clin Oncol, 128, pp. 603-609.
8. Weide, R., Heymanns, J., Gores, A. and Köppler, H. (2002) Bendamustine, mitoxantrone and rituximab (BMR): A new effective regimen for refractory or relapsed indolent lymphomas. Leuk Lymphoma, 43, pp. 327-331.
9. Weide, R., Pandorf, A., Heymanns, J. and Köppler, H. (2004) Bendamustine/mitoxantrone/rituximab (BMR): A very effective, well tolerated outpatient immuno-chemotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma, 45, pp. 2445-2449.
10. Cheson, B. D., Horning, S. J. and Coiffier, B. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol, 17, pp. 1244-1253.
11. Balfour, J. A. and Goa, K. L. (2001) Bendamustine. Drugs, 61, pp. 631-640.
12. Ozegowski, W. and Krebs, D. (1971) IMET 3393, gamma-(1-methyl-5-bis- (β-chloräthyl)-amino-benzimidazolyl(2) -buttersäure-hydrochlorid, ein neues Zytostatikum aus der Reihe der Benzimidazol-Loste. Zbl Pharm, 110, pp. 1013-1019.
13. Anger, G., Hesse, P., Köhler, P. and Baufeld, H. (1967) Erste klinische Erfahrungen mit einem neuen Zytostatikum. Deutsch Gesundheitswes, 22, pp. 1079-1084.
14. Ruffert, K., Jahn, H. and Syrbe, G. (1989) Cytostasan (Bendamustin) in der alternativtherapie maligner non-Hodgkin-lymphoma. Z Klin Med, 44, pp. 671-674.
15. Anger, G., Fink, R. and Fleischer, J. (1975) Vergleichsuntersuchungen zwischen cytostasan und cyclophosphamid bei der chronischen lymphadenose, dem plasmozytom, der lymphogranulomatose und dem bronchialkarzinom. Deutsch Gesundheitswes, 30, pp. 1280-1285.
16. Friedberg, J. W., Cohen, P. and Cheson, B. D. (2005) Bendamustine HCL (Treanda™) treatment results in high rates of objective response in patients with rituximab-refractory and alkylator-refractory indolent B-cell non-Hodgkin's lymphoma (NHL): Results from a phase II multicenter single-agent study (SDX-105-01). Blood, 106
17. Weide, R., Heymanns, J. and Koeppler, H. (1999) Successful treatment of alkylating agent resistant low grade B-cell non-hodgkin's lymphomas with bendamustin/mitoxantrone/rituximab (BMR). Onkologie, 22
18. Rummel, M. J., Al-Batran, S. E. and Kim, S. Z. (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol, 23, pp. 3383-3389.
19. Robinson, K. S., Williams, M. E. and Cohen, P. (2005) Bendamustine HCL (Treanda™) treatment in combination with rituximab results in objective responses in patients with refractory/relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma: Results from phase II multicenter study (SDX-105-02). Blood, 106